Advice

following an abbreviated submission:

zanubrutinib (Brukinsa®) is accepted for use within NHSScotland.

Indication under review: as monotherapy for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Zanubrutinib offers an additional treatment choice in the therapeutic class of Bruton’s tyrosine kinase inhibitors (BTKi).

Another BTKi was accepted for use under the end of life and ultra-orphan process.

This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.

Download detailed advice289KB (PDF)

Download

Medicine details

Medicine name:
zanubrutinib (Brukinsa)
SMC ID:
SMC2819
Indication:

As monotherapy for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy

Pharmaceutical company
BeiGene UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Abbreviated
Status
Accepted
Date advice published
11 August 2025